Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bumetanide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corstasis' FDA-Approved Bumetanide Nasal Spray NDA
Details : RSQ-777 (bumetanide is given to help treat edema and swelling that is caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.
Product Name : RSQ-777
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2025
Lead Product(s) : Bumetanide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LOOKING FOR A SUPPLIER?